CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer | Zendy

Gerard M. Walls | Zendy; Jamie B. Oughton | Zendy; Anthony J. Chalmers | Zendy; Sarah Brown | Zendy; Fiona Collinson | Zendy; Martin Förster | Zendy; K. Franks | Zendy; Alexandra Gilbert | Zendy; Gerard G. Hanna | Zendy; Nicola Hannaway | Zendy; Stephen Harrow | Zendy; Tom Haswell | Zendy; Crispin T. Hiley | Zendy; Samantha Hinsley | Zendy; Matthew Krebs | Zendy; Geraldine Murden | Zendy; Rachel Phillip | Zendy; Anderson J. Ryan | Zendy; Ahmed Salem | Zendy; David SebagMontefiore | Zendy; Paul Shaw | Zendy; Chris Twelves | Zendy; Katrina Walker | Zendy; Robin Young | Zendy; C. FaivreFinn | Zendy; Alastair Greystoke | Zendy

Open Access

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Author(s) -

Gerard M. Walls,

Jamie B. Oughton,

Anthony J. Chalmers,

Sarah Brown,

Fiona Collinson,

Martin Förster,

K. Franks,

Alexandra Gilbert,

Gerard G. Hanna,

Nicola Hannaway,

Stephen Harrow,

Tom Haswell,

Crispin T. Hiley,

Samantha Hinsley,

Matthew Krebs,

Geraldine Murden,

Rachel Phillip,

Anderson J. Ryan,

Ahmed Salem,

David SebagMontefiore,

Paul Shaw,

Chris Twelves,

Katrina Walker,

Robin Young,

C. FaivreFinn,

Alastair Greystoke

Publication year - 2020

Publication title -

clinical and translational radiation oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.336

H-Index - 15

ISSN - 2405-6308

DOI - 10.1016/j.ctro.2020.09.006

Subject(s) - radiation therapy , medicine , lung cancer , phase (matter) , oncology , chemistry , organic chemistry

Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research